Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

ICRMYELOMA

Financiado

Cerrado

Sequence of Mutational Events and Sub clonal Architecture in Plasma Cell Myelom...

Sequence of Mutational Events and Sub clonal Architecture in Plasma Cell Myeloma "Plasma cell myeloma (PCM) is an incurable malignancy. Cytogenetics, molecular genetics and single nucleotide polymorphism arrays have shown significant genetic complexity in PCM. However, these screens reflect only the predominan... ver más

31/07/2014

ICR

209K€

Presupuesto del proyecto: 209K€

Líder del proyecto

INSTITUTE OF CANCER RESEARCH THE ROYAL CANCER... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2014-07-31 No tenemos la información de la convocatoria

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

ICR

0.00€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

BCLLatlas Single cell genomics to comprehensively understand healthy B... 8M€ Cerrado

CLL_INCLONEL Identification and functional dissection of key genetic even... 261K€ Cerrado

MMSC Novel therapeutic antibodies for multiple myeloma 100K€ Cerrado

bECOMiNG spontaneous Evolution and Clonal heterOgeneity in MoNoclonal... 2M€ Cerrado

TOP TOwards Personalized medicine defining the role of the bone... 275K€ Cerrado

PID2021-125277OB-I00 DESCIFRANDO EL PAPEL Y LA REGULACION DE LA ARQUITECTURA DEL... 303K€ Cerrado

Líder del proyecto

INSTITUTE OF CANCER RESEARCH THE ROYAL CANCER... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 209K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto "Plasma cell myeloma (PCM) is an incurable malignancy. Cytogenetics, molecular genetics and single nucleotide polymorphism arrays have shown significant genetic complexity in PCM. However, these screens reflect only the predominant clonal population and genetic-based prognostic classification of PCM can predict the outcome only in a subset of cases. To better understand the oncogenesis of PCM combined investigation of genetic abnormalities at single cell level is needed. The original theory of clonal evolution in cancer proposed a stepwise, linear acquisition of mutations; however a branching sub-clonal genetic structure has recently been demonstrated in the leukaemia-propagating (‘stem’) cells of acute lymphoblastic leukaemia. The aim of this project is (i) to determine whether sub-clonal heterogeneity is a feature of PCM, (ii) to determine whether there is any particular order of acquisition of translocations, copy number alterations and gene mutations, (iii) to examine clonal heterogeneity with progression of disease and (iv) to determine whether myeloma propagating cells also show sub-clonal genetic heterogeneity. Purified plasma cells from patients with PCM as well as monoclonal gammopathy of undetermined significance and plasma cell leukaemia will be investigated. Specific abnormalities, identified by pre-screening tests, will be analyzed at single cell level using multicolour-FISH and a high-throughput microfluidic platform. Serial transplantation of malignant cells into NOD/SCID mice will be used for investigation of sub-clonal heterogeneity of myeloma propagating cells. We anticipate that this project will identify key mechanisms in myeloma progression potentially leading to the introduction of a much more precise prognostic classification and residual disease monitoring. If myeloma stem cells are genetically diverse, this offers the potential to alter treatment strategies and will have major implications for management of patients with PCM."

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores